PL2403529T3 - Przeciwciało monoklonalne przeciw czynnikowi RhD - Google Patents

Przeciwciało monoklonalne przeciw czynnikowi RhD

Info

Publication number
PL2403529T3
PL2403529T3 PL10715299T PL10715299T PL2403529T3 PL 2403529 T3 PL2403529 T3 PL 2403529T3 PL 10715299 T PL10715299 T PL 10715299T PL 10715299 T PL10715299 T PL 10715299T PL 2403529 T3 PL2403529 T3 PL 2403529T3
Authority
PL
Poland
Prior art keywords
rhesus
monoclonal antibody
monoclonal
antibody
Prior art date
Application number
PL10715299T
Other languages
English (en)
Inventor
Christine Gaucher
Sylvie Jorieux
Romeuf Christophe De
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of PL2403529T3 publication Critical patent/PL2403529T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL10715299T 2009-03-06 2010-03-05 Przeciwciało monoklonalne przeciw czynnikowi RhD PL2403529T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0951412A FR2942799B1 (fr) 2009-03-06 2009-03-06 Anticorps monoclonal anti-rhesus d
PCT/FR2010/050376 WO2010100383A1 (fr) 2009-03-06 2010-03-05 Anticorps monoclonal anti-rhesus d
EP10715299.3A EP2403529B1 (fr) 2009-03-06 2010-03-05 Anticorps monoclonal anti-rhesus d

Publications (1)

Publication Number Publication Date
PL2403529T3 true PL2403529T3 (pl) 2015-07-31

Family

ID=40902101

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10715299T PL2403529T3 (pl) 2009-03-06 2010-03-05 Przeciwciało monoklonalne przeciw czynnikowi RhD

Country Status (16)

Country Link
US (1) US8404241B2 (pl)
EP (1) EP2403529B1 (pl)
JP (1) JP5474100B2 (pl)
KR (1) KR101297343B1 (pl)
CN (1) CN102341121B (pl)
AR (1) AR076083A1 (pl)
AU (1) AU2010219518B2 (pl)
BR (1) BRPI1009241B1 (pl)
CA (1) CA2753700C (pl)
DK (1) DK2403529T3 (pl)
ES (1) ES2533528T3 (pl)
FR (1) FR2942799B1 (pl)
IL (1) IL214755A (pl)
PL (1) PL2403529T3 (pl)
TW (1) TWI441921B (pl)
WO (1) WO2010100383A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
HK1204990A1 (en) * 2012-03-26 2015-12-11 Sanofi Stable igg4 binding agent formulations
MX368259B (es) * 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
CN114409791B (zh) * 2022-01-26 2023-01-24 南京医科大学 一种全人源抗人红细胞RhD全分子IgG及其制备方法和应用
CN119176879B (zh) * 2024-09-05 2025-08-05 西安市中心血站（陕西省血液中心） 一种中和抗d抗体的抗独特型抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2861079B1 (fr) * 2003-10-20 2007-09-28 Lab Francais Du Fractionnement Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
EA014182B1 (ru) * 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
ZA200709956B (en) * 2005-05-20 2009-02-25 Genentech Inc Pretreatment of a biological sample from an autoimmune disease subject
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody

Also Published As

Publication number Publication date
CN102341121A (zh) 2012-02-01
DK2403529T3 (en) 2015-04-13
JP5474100B2 (ja) 2014-04-16
CN102341121B (zh) 2015-07-08
KR20110140125A (ko) 2011-12-30
CA2753700C (fr) 2014-04-22
EP2403529A1 (fr) 2012-01-11
BRPI1009241A2 (pt) 2016-10-11
WO2010100383A1 (fr) 2010-09-10
IL214755A0 (en) 2011-11-30
US8404241B2 (en) 2013-03-26
IL214755A (en) 2017-03-30
JP2012519478A (ja) 2012-08-30
KR101297343B1 (ko) 2013-08-20
AU2010219518B2 (en) 2012-09-20
AR076083A1 (es) 2011-05-18
FR2942799A1 (fr) 2010-09-10
ES2533528T3 (es) 2015-04-10
BRPI1009241B1 (pt) 2019-11-05
EP2403529B1 (fr) 2014-12-31
FR2942799B1 (fr) 2011-02-25
TWI441921B (zh) 2014-06-21
US20110311556A1 (en) 2011-12-22
CA2753700A1 (fr) 2010-09-10
AU2010219518A1 (en) 2011-10-20
TW201043693A (en) 2010-12-16

Similar Documents

Publication Publication Date Title
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2331579A4 (en) MONOCLONAL ANTIBODIES
ZA201202227B (en) Monoclonal antibodies
IL217919A0 (en) Humanized anti-cdcp1 antibodies
IL207217A0 (en) Humanized anti-c5ar antibodies
ZA201107529B (en) Humanized axl antibodies
IL220404A (en) Antiseptic antibodies
PL2510011T3 (pl) Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
ZA201104545B (en) Anti-siglec-15 antibody
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
IL217934A0 (en) NON-CROSS-REACTIVE ANTI IgG ANTIBODIES
GB0920324D0 (en) Antibodies
EP2463369A4 (en) HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS
HUE036392T2 (hu) Humanizált anti-amiloid ß oligomer antitest
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
IL214755A0 (en) Anti-rhesus d monoclonal antibody
GB2473934B (en) Anti-VEEV antibody
GB0804684D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
TWI348915B (en) Anti-vegf monoclonal antibody
GB0911712D0 (en) Antibody